ABSTRACT
Recently, there has been increased implementation of bone marrow cell (BMC) transplantations in clinical settings to treat leukemia, lymphoma, and primary immunode—ciency disease.1 BMCs consist of various cell populations including hematopoietic stem cells (HSCs), mesenchymal stem cells, also known as multipotent stromal cells (MSCs), and endothelial progenitor cells (EPCs).2 Human HSCs
7.1 Introduction .................................................................................................. 193 7.2 Ischemia-Induced Spontaneous BMC Mobilization ..................................... 194 7.3 Molecular Therapies to Stimulate Endogenous BMC Mobilization ............ 197
7.3.1 Administration of Antibodies or Inhibitors of Receptor-Ligand Bonds ................................................................... 197
7.3.2 Administration of Chemokines to Regulate Phenotypic Activity of BMCs .............................................................................. 198 7.3.2.1 Action of Chemokines ....................................................... 198 7.3.2.2 Coadministration of Chemokines ......................................202 7.3.2.3 Sustained Delivery of Chemokines ...................................202
